Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-Compromise
NL-OMON25136Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of Nanogam and anti-COVID-19 immune globulin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Amsterdam University Medical Center. Started Apr 2021; status: recruiting.
02
Drugs
Nanogamanti-COVID-19 immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON25136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25136.